Domov › Nemalicelični pljučni rak › Michigan

Klinične študije za Nemalicelični pljučni rak v Michigan

101 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v Michigan.

Mesta v Michigan

Uradno besedilo študije (angleško)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Bronson Battle Creek, Battle Creek
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
in še 50

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health Medical Center - Brighton, Brighton
in še 7

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07293247

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06465069

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

South Texas Accelerated Research Therapeutics (START), Grand Rapids

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #65, Detroit
Exelixis Clinical Site #13, Detroit

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT05176483

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

BAMF Health, Grand Rapids

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07189871

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Bronson Battle Creek, Battle Creek
Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo
in še 7

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07388524

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

University of Michigan Rogel Cancer Center, Ann Arbor
Bronson Battle Creek, Battle Creek
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
in še 38

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06498635

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site, Detroit

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06996782

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Center 8, Farmington Hills
ALX Center 3, Grand Rapids

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07085091

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Karmanos Cancer Institute, Detroit

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07361497

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Henry Ford Hospital - Detroit /ID# 271642, Detroit

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT06772623

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Trinity Health Ann Arbor Hospital, Ann Arbor
Karmanos Cancer Institute, Detroit
Henry Ford Health, Detroit

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT06881784

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Corewell Health - Butterworth Hospital, Grand Rapids
Corewell Health - Lemmen Holton Cancer Pavilion, Grand Rapids
Corewell Health - Research Specimen Processing Area, Grand Rapids
in še 2

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

University of Michigan Health System, Ann Arbor
Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667076

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Saginaw

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Karmanos Cancer Institute, Detroit

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06890598

Pan-tumor MRD Study

The Cancer & Hematology Centers (CHC), Grand Rapids

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
in še 48

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT03191149

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Profound Research LLC - MHP MedOnc Royal Oak - Oakland Medical Group Location, Royal Oak

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06561386

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Dearborn
Research Site, Farmington Hills
Research Site, Grand Rapids

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06357533

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

University of Michigan Health Systems, Ann Arbor

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07140016

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

START Midwest, Grand Rapids

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06128551

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Barbara Ann Karmanos Cancer Center, Detroit
START Midwest, Grand Rapids

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07488676

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0293, Detroit

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06875310

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

University of Michigan Medical School Rogel Cancer Center, Ann Arbor

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07629960

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Detroit
Research Site, Grand Rapids
Research Site, Saginaw

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Ann Arbor
Clinical Study Site, Detroit
Clinical Study Sites, Detroit

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06767514

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Karmanos Cancer Institute, Detroit

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06855771

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

START Midwest, Grand Rapids

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT05267626

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

START Midwest, Grand Rapids

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07349537

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

BAMF Health, Grand Rapids

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07020117

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT05786924

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer & Hematology Centers of Western Michigan - East /ID# 261826, Grand Rapids

Vključevanje udeležencevFaza 2/3

Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06236438

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Cancer & Hematology Centers of Western Michigan, Grand Rapids

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT05059444

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

University of Michigan, Ann Arbor

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 10. sep. 2026 · NCT04302025

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

START | Midwest, Grand Rapids

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 10. sep. 2026 · NCT06914128

A Phase 1/1b Study of IAM1363 in HER2 Cancers

University of Michigan, Ann Arbor
Henry Ford Cancer Institute, Detroit
START - Midwest Cancer Research Center, Grand Rapids

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06253871

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

Profound Research, LLC, Farmington Hills

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07541170

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Profound Research, LLC, Farmington Hills

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06793215

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.